Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | PPARD | Q03181 | 3/20 | 0.52 |
| ▸ | PPARA | Q07869 | 10/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 4/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405042 | 0.91 | CHRM4 (0.49) | CHRM4NPC1ALDH1A1GAAHRH3 | |
| SCHEMBL3405620 | 0.87 | CHRM4 (0.47) | CHRM4NPC1SLC2A1RAB9A | |
| SCHEMBL13071657 | 0.87 | CHRM4 (0.53) | CHRM4NPC1ALDH1A1GAAHRH3 | |
| SCHEMBL3400068 | 0.87 | CYP1A2 (0.58) | CHRM4NPC1PPARDPPARAHRH3 | |
| SCHEMBL3404992 | 0.85 | HRH3 (0.55) | CHRM4NPC1ALDH1A1HRH3SLC2A1 | |
| SCHEMBL3401247 | 0.85 | PPARD (0.48) | CHRM4NPC1ALDH1A1PPARDPPARA | |
| SCHEMBL3399951 | 0.84 | RAB9A (0.50) | CHRM4NPC1PPARAHRH3SLC2A1 | |
| SCHEMBL3404512 | 0.84 | HRH3 (0.62) | CHRM4NPC1HRH3SLC2A1RAB9A | |
| SCHEMBL3405286 | 0.84 | SLC2A1 (0.50) | CHRM4NPC1HRH3SLC2A1RAB9A | |
| SCHEMBL3401829 | 0.84 | SLC2A1 (0.50) | CHRM4NPC1GAAPPARAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100297035-A1 | Thiazole Amides, Imidazole Amides and Related Analogues | LIGAND PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
| WO-2006089076-A9 | THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES | NEUROGEN CORP (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297035-A1 | Thiazole Amides, Imidazole Amides and Related Analogues | HRH3, HRH4, HRH2 | CHRM4 289/4885NPC1 2005/4885ALDH1A1 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.